Compare Arm Holdings plc (ARM) vs Summit Therapeutics Inc (SMMT) Price & Performance

ARM Holdings trades at $272.10, up 1.59% today, with a bullish technical signal from moving averages and recent earnings beats. The company reported robust revenue growth, with fiscal 2025 revenue of $4.01 billion and net income of $792 million, and strong profitability margins. Analyst consensus is bullish with a 70.37% buy rating and a $329.80 price target, though valuation multiples remain elevated.

The outlook is positive given ARM's leadership in AI chip architecture and projected revenue growth to $5.2 billion in 2026. Key risks include high valuation multiples, smartphone market headwinds, and execution challenges in custom chip development. Upside potential exists if AI-driven demand continues, but investors should weigh growth prospects against premium pricing.

Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.

The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.